InsiderPulse
Dashboard

MDGL

Madrigal Pharmaceuticals, Inc.

Health CareRussell 2000

Madrigal Pharmaceuticals, Inc. insider trading

Madrigal Pharmaceuticals, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in West Conshohocken, PA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent MDGL insider transactions

One insider traded MDGL on the open market between Sep 09, 2026 and Sep 11, 2026 — 24 sales worth $6.2M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$6.2M

24 of 24 on a 10b5-1 plan

Net
−$6.2M
Insiders
1

Open-market purchases (code P) and sales (code S) from Madrigal Pharmaceuticals, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every MDGL Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

MDGL insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 14 insiders traded MDGL on the open market: 54 purchases worth $61.9M and 312 sales worth $219.4M, 235 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 54 purchases ($61.9M) and 245 sales ($186.2M), by 11 insiders.

QuarterBoughtSold
Q2 2026—−$3.9M14 sales · 13 on a plan
Q1 2026—−$28.3M83 sales · 75 on a plan
Q4 2025—−$41.3M70 sales · 58 on a plan
Q3 2025+$61.9M54 buys−$112.7M78 sales · 71 on a plan
Q2 2025——
Q1 2025—−$25.8M56 sales · 13 on a plan
Q4 2024—−$5.8M10 sales · 5 on a plan
Q3 2024—−$1.6M1 sale
Largest purchase
+$10M of MDGL by Baker Bros. Advisors (GP) LLC (Director) on Aug 18, 2025.
Largest sale
−$10.8M of MDGL by Friedman Paul A (Director) on Aug 13, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Soergel David10b5-1

    Chief Medical Officer

    −$516.6K

    Jun 01, 2026

    1,042 sh · $495.74

  • Levy Richard S10b5-1

    Director

    −$774.8K

    May 22, 2026

    1,497 sh · $517.59

  • Levy Richard S10b5-1

    Director

    −$405.7K

    May 22, 2026

    782 sh · $518.76

  • Levy Richard S10b5-1

    Director

    −$373.7K

    May 22, 2026

    723 sh · $516.87

  • Levy Richard S10b5-1

    Director

    −$339K

    May 22, 2026

    657 sh · $515.92

  • Levy Richard S10b5-1

    Director

    −$312K

    May 22, 2026

    610 sh · $511.40

  • Levy Richard S10b5-1

    Director

    −$225K

    May 22, 2026

    439 sh · $512.50

  • Levy Richard S10b5-1

    Director

    −$176.5K

    May 22, 2026

    343 sh · $514.67

  • Levy Richard S10b5-1

    Director

    −$162.6K

    May 22, 2026

    320 sh · $508.24

  • Levy Richard S10b5-1

    Director

    −$77.1K

    May 22, 2026

    151 sh · $510.36

  • Levy Richard S10b5-1

    Director

    −$41.6K

    May 22, 2026

    80 sh · $519.98

  • Levy Richard S10b5-1

    Director

    −$20.5K

    May 22, 2026

    40 sh · $512.97

  • Levy Richard S10b5-1

    Director

    −$20.3K

    May 22, 2026

    40 sh · $506.68

  • Soergel David

    Chief Medical Officer

    −$435.4K

    May 18, 2026

    844 sh · $515.90

  • Sibold William John

    President and CEO · Director

    −$718.3K

    Mar 06, 2026

    1,663 sh · $431.94

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Madrigal Pharmaceuticals, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
West Conshohocken, PA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001157601
Previously filed as
SYNTA PHARMACEUTICALS CORP

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought MDGL

What the stock actually did in the 90 days following each open-market purchase

Don't check MDGL — let it ping you

Get told the moment an insider moves on MDGL

Pro watches Madrigal Pharmaceuticals, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add MDGL to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track MDGL on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read MDGL insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

MRUSNUVLPCVXPTGXRVMDRYTMSMMTSNDXSRRKTGTXVERAVKTX
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are MDGL insiders buying or selling?
Between Sep 09, 2026 and Sep 11, 2026, 1 Madrigal Pharmaceuticals, Inc. insider made no open-market purchases and 24 sales worth $6.2M, a net sale of $6.2M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much MDGL stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 14 Madrigal Pharmaceuticals, Inc. insiders made 54 open-market purchases worth $61.9M and 312 sales worth $219.4M. 235 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 54 purchases ($61.9M) and 245 sales ($186.2M). The largest purchase was Baker Bros. Advisors (GP) LLC buying $10M on Aug 18, 2025. The largest sale was Friedman Paul A selling $10.8M on Aug 13, 2025.
What was the largest recent MDGL insider trade?
Sibold William John (President and CEO · Director) sold $837.3K of MDGL stock on Sep 11, 2026 at about $544.02 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy MDGL shares?
No open-market purchase by a Madrigal Pharmaceuticals, Inc. insider appears in the filings from Sep 09, 2026 to Sep 11, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Baker Bros. Advisors (GP) LLC buying $5.2M on Aug 20, 2025.
Where does MDGL insider trading data come from?
From the Form 4 filings Madrigal Pharmaceuticals, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.